Premium
CAR T‐CELLS ARE ARRIVING. IS ALLOGENEIC TRANSPLANT AN OBSOLETE APPROACH FOR DE NOVO/TRANSFORMED DLBCL IN THE CAR T‐CELLS ERA? LONG‐TERM FOLLOW‐UP OF A SINGLE CENTRE UNIT
Author(s) -
PrietoGarcía L.,
Alcoceba M.,
PérezLópez E.,
LópezCorral L.,
Delgado M.,
SánchezGuijo F.,
Martín A.,
NavarroBailón A.,
Baile M.,
LópezParra M.,
Tamayo P.,
Gutiérrez N.C.,
Vázquez L.,
Cabrero M.,
Martín A.,
Caballero D.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.191_2631
Subject(s) - medicine , lymphoma , chimeric antigen receptor , transplantation , chemotherapy , stem cell , refractory (planetary science) , oncology , surgery , cancer , immunotherapy , biology , astrobiology , genetics